Pax-5 is a potent regulator of E-cadherin and breast cancer malignant processes-Reference-Cited by-同舟云学术

Pax-5 is a potent regulator of E-cadherin and breast cancer malignant processes

Published:2017-01-05 Issue:7 Volume:8 Page:12052-12066
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Benzina Sami¹²,Beauregard Annie-Pier¹²,Guerrette Roxann¹²,Jean Stéphanie¹²,Faye Mame Daro¹²,Laflamme Mark¹³,Maïcas Emmanuel¹²⁴,Crapoulet Nicolas²,Ouellette Rodney J.¹²,Robichaud Gilles A.¹²

Affiliation:

1. Université de Moncton, Département de chimie et biochimie, Moncton, NB, E1A 3E9, Canada

2. Atlantic Cancer Research Institute, Moncton, NB, E1C 8×3, Canada

3. Department of Fisheries and Oceans Canada, Molecular Biology Unit, Moncton, NB, E1C 9B6, Canada

4. Georges-L.-Dumont University Hospital Centre, Pathology Department, Moncton, NB, E1C 2Z3, Canada

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling pathogenesis and therapeutic targets of metastatic breast cancer through sparse modeling of genomic landscape;Computational and Structural Biotechnology Reports;2024-12

2. Brevilin A Inhibits Prostate Cancer Progression by Decreasing PAX5-Activated SOX4;Molecular Biotechnology;2024-05-14

3. Identification of Tissue miRNA Signatures for Pancreatic Ductal Adenocarcinoma;Cancers;2024-02-18

4. Unveiling Pathogenesis and Therapeutic Targets of Metastatic Breast Cancer Through Sparse Modelling of Genomic Landscape;2023-12-16

5. PAX5 and CD70 are expressed in thymic carcinoma but not in atypical thymoma (WHO type B3 thymoma): an immunohistochemical analysis of 60 cases;Journal of Clinical Pathology;2023-09-11